Guggenheim Forecasts Strong Price Appreciation for InflaRx (NASDAQ:IFRX) Stock

InflaRx (NASDAQ:IFRX) had its target price raised by equities research analysts at Guggenheim from $10.00 to $22.00 in a research report issued to clients and investors on Monday,Benzinga reports. The firm presently has a “buy” rating on the stock.

Several other analysts have also issued reports on the stock. HC Wainwright assumed coverage on shares of InflaRx in a report on Tuesday, September 2nd. They issued a “buy” rating and a $6.00 price objective on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of InflaRx in a research report on Wednesday. Finally, Wall Street Zen downgraded shares of InflaRx from a “hold” rating to a “sell” rating in a report on Saturday. Five analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, InflaRx presently has a consensus rating of “Moderate Buy” and a consensus price target of $8.60.

InflaRx Stock Up 2.5%

IFRX stock opened at $1.23 on Monday. InflaRx has a 52-week low of $0.71 and a 52-week high of $2.82. The stock has a market cap of $82.57 million, a price-to-earnings ratio of -1.54 and a beta of 1.38. The business has a fifty day moving average of $1.38 and a two-hundred day moving average of $1.18.

InflaRx (NASDAQ:IFRX) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($0.24) EPS for the quarter, meeting the consensus estimate of ($0.24). The business had revenue of $0.05 million during the quarter, compared to analyst estimates of $0.02 million. As a group, sell-side analysts anticipate that InflaRx will post -1.04 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in IFRX. Cubist Systematic Strategies LLC increased its position in shares of InflaRx by 33.9% in the 1st quarter. Cubist Systematic Strategies LLC now owns 30,053 shares of the company’s stock valued at $31,000 after purchasing an additional 7,616 shares during the last quarter. XTX Topco Ltd acquired a new stake in InflaRx in the first quarter valued at $38,000. Concurrent Investment Advisors LLC purchased a new stake in InflaRx during the 2nd quarter worth about $65,000. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of InflaRx by 158.3% during the 2nd quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 150,000 shares of the company’s stock worth $118,000 after acquiring an additional 91,927 shares in the last quarter. Finally, Adage Capital Partners GP L.L.C. acquired a new position in shares of InflaRx during the 2nd quarter worth about $262,000. Hedge funds and other institutional investors own 42.39% of the company’s stock.

About InflaRx

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.